Revenue - Revenue Recognition (Details) - Revenue Benchmark	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Customer Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%
Customer Concentration Risk | Biologics
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	39.00%	37.00%
Customer Concentration Risk | Generics
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	16.00%	18.00%
Customer Concentration Risk | Pharma
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	26.00%	25.00%
Customer Concentration Risk | Contract-Manufactured Products
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	19.00%	20.00%
Product Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%
Product Concentration Risk | High-Value Product ("HVP") Components
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	45.00%	47.00%
Product Concentration Risk | High-Value Product ("HVP") Delivery Devices
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	14.00%	11.00%
Product Concentration Risk | Standard Packaging
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	22.00%	22.00%
Product Concentration Risk | Contract-Manufactured Products
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	19.00%	20.00%
Geographic Concentration Risk
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	100.00%	100.00%
Geographic Concentration Risk | Americas
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	49.00%	43.00%
Geographic Concentration Risk | Europe, Middle East, Africa
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	44.00%	48.00%
Geographic Concentration Risk | Asia Pacific
Disaggregation of Revenue [Line Items]
Concentration risk, percentage	7.00%	9.00%